CXCR4 and non-small cell lung carcinoma: Similarly, Andtbacka et al. showed that mavorixafor, a CXCR4 inhibitor, enhances immune infiltration in tumors by increasing antigen presentation, CD8+ T-cell activity, and IFN-γ expression, with combination therapy improving responses to ICIs in solid tumors, including NSCLC (Andtbacka et al., 2022).